|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Alder_Bio_Pharmaceuticals
ongoing
completed
Phase 3
planned
NC T12345678
|
|
gptkbp:collaborations
|
gptkb:FDA
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:Research_Institute
|
|
gptkbp:complications
|
allergic reactions
liver enzyme elevation
thrombocytopenia
neutropenia
serious infections
|
|
gptkbp:developed_by
|
gptkb:Alder_Bio_Pharmaceuticals
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:effective_date
|
2025-01-01
|
|
gptkbp:frequency
|
once every four weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-1010
|
|
gptkbp:indication
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
psoriasis
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
reduces symptoms of Crohn's disease
reduces symptoms of psoriasis
reduces symptoms of ulcerative colitis
|
|
gptkbp:is_tested_for
|
Phase 2
|
|
gptkbp:is_used_for
|
treatment of autoimmune diseases
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:market
|
pending
|
|
gptkbp:marketed_as
|
Alder's IL-23 inhibitor
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California
gptkb:Cleveland_Clinic
|
|
gptkbp:research_focus
|
immunology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
injection site reactions
|
|
gptkbp:social_structure
|
gptkb:Ig_G1
|
|
gptkbp:status
|
gptkb:legal_case
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:IL-23
p19 subunit of IL-23
|
|
gptkbp:bfsParent
|
gptkb:ALX-0721
|
|
gptkbp:bfsLayer
|
5
|